Recurrence and progression rates vary widely among different histological subtypes of bladder cancer (BC). Normal-appearing mucosa in non-muscle invasive bladder cancer and muscle-invasive bladder ...
Partial bladder outlet obstruction due to prostate hyperplasia or posterior urethral valves, is a widespread cause of urinary dysfunction, patient discomfort and also responsible for immense health ...
A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but ...
A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...
Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer. Results of a phase II study of pralatrexate in patients with ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.
Noninvasive treatment options for NGB dysfunction include intermittent catheterization, Crede and Valsalva, indwelling catheterization, lifestyle changes/behavioral modification, and oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results